TY  - GEN
AU  - Álvarez-Vázquez, Andrea
AU  - San-Segundo, Laura
AU  - Cerveró-García, Pilar
AU  - Flores-Hernández, Raquel
AU  - Ollauri-Ibáñez, Claudia
AU  - Segura-Collar, Berta
AU  - Hubert, Christopher G
AU  - Morrison, Gillian
AU  - Pollard, Steven M
AU  - Lathia, Justin D
AU  - Sánchez-Gómez, Pilar
AU  - Tabernero, Arantxa
AU  - Álvarez-Vázquez, Andrea
AU  - San-Segundo, Laura
AU  - Cerveró-García, Pilar
AU  - Flores-Hernández, Raquel
AU  - Ollauri-Ibáñez, Claudia
AU  - Segura-Collar, Berta
AU  - Hubert, Christopher G
AU  - Morrison, Gillian
AU  - Pollard, Steven M
AU  - Lathia, Justin D
AU  - Tabernero, Arantxa
PY  - 2024
DO  - 10.1093/neuonc/noae060
SN  - 1522-8517
UR  - https://hdl.handle.net/20.500.12105/25527
AB  - Background: Glioblastoma (GBM) commonly displays epidermal growth factor receptor (EGFR) alterations (mainly amplification and EGFRvIII) and TAT-Cx43266-283 is a Src-inhibitory peptide with antitumor properties in preclinical GBM models. Given the...
LA  - eng
PB  - Oxford University Press
KW  - EGFR
KW  - NSCs
KW  - Src
KW  - Cell-penetrating peptides
KW  - Glioblastoma
KW  - Animals
KW  - Brain Neoplasms
KW  - ErbB Receptors
KW  - Erlotinib Hydrochloride
KW  - Gene Amplification
KW  - Glioblastoma
KW  - Humans
KW  - Mice
KW  - Neoplastic Stem Cells
KW  - Temozolomide
KW  - Tumor Cells, Cultured
KW  - Xenograft Model Antitumor Assays
TI  - EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models
TY  - research article
ER  -